Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163777

Authors

Mohamed Haider

Amr Elsherbeny

Valeria Pittala

Valeria Consoli

Maha Ali Alghamdi

Zahid Hussain

Ghalia Khoder

Khaled Greish

Affiliations

Soon will be listed here.

Abstract

Lung cancer (LC) is one of the leading causes of cancer occurrence and mortality worldwide. Treatment of patients with advanced and metastatic LC presents a significant challenge, as malignant cells use different mechanisms to resist chemotherapy. Drug resistance (DR) is a complex process that occurs due to a variety of genetic and acquired factors. Identifying the mechanisms underlying DR in LC patients and possible therapeutic alternatives for more efficient therapy is a central goal of LC research. Advances in nanotechnology resulted in the development of targeted and multifunctional nanoscale drug constructs. The possible modulation of the components of nanomedicine, their surface functionalization, and the encapsulation of various active therapeutics provide promising tools to bypass crucial biological barriers. These attributes enhance the delivery of multiple therapeutic agents directly to the tumor microenvironment (TME), resulting in reversal of LC resistance to anticancer treatment. This review provides a broad framework for understanding the different molecular mechanisms of DR in lung cancer, presents novel nanomedicine therapeutics aimed at improving the efficacy of treatment of various forms of resistant LC; outlines current challenges in using nanotechnology for reversing DR; and discusses the future directions for the clinical application of nanomedicine in the management of LC resistance.

Citing Articles

CD44-Receptors-Mediated Multiprong Targeting Strategy Against Breast Cancer and Tumor-Associated Macrophages: Design, Optimization, Characterization, and Cytologic Evaluation.

Hussain Z, Abdulrahim Abdul Moti L, Jagal J, Thu H, Khan S, Kazi M Int J Nanomedicine. 2025; 20:991-1020.

PMID: 39881963 PMC: 11776558. DOI: 10.2147/IJN.S480553.

Targeting PGK1: A New Frontier in Breast Cancer Therapy Under Hypoxic Conditions.

Cui J, Chai S, Liu R, Shen G Curr Issues Mol Biol. 2024; 46(11):12214-12229.

PMID: 39590319 PMC: 11593045. DOI: 10.3390/cimb46110725.

Chitosan Nanoparticles for Targeted Cancer Therapy: A Review of Stimuli-Responsive, Passive, and Active Targeting Strategies.

Al-Shadidi J, Al-Shammari S, Al-Mutairi D, Alkhudhair D, Thu H, Hussain Z Int J Nanomedicine. 2024; 19:8373-8400.

PMID: 39161363 PMC: 11332424. DOI: 10.2147/IJN.S472433.

Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways.

Mohanty P, Pande B, Acharya R, Bhaskar L, Verma H Diseases. 2024; 12(5).

PMID: 38785748 PMC: 11119248. DOI: 10.3390/diseases12050093.

Recent Advancement in Inhaled Nano-drug Delivery for Pulmonary, Nasal, and Nose-to-brain Diseases.

Fu Q, Liu Y, Peng C, Muluh T, Anayyat U, Liang L Curr Drug Deliv. 2024; 22(1):3-14.

PMID: 38275044 DOI: 10.2174/0115672018268047231207105652.

References

Awasthi Y, Singh S, Ahmad H, Moller P . Immunocytochemical evidence for the expression of GST1, GST2, and GST3 gene loci for glutathione S-transferase in human lung. Lung. 1987; 165(6):323-32. DOI: 10.1007/BF02714448. View

Dearden S, Stevens J, Wu Y, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-6. PMC: 3755331. DOI: 10.1093/annonc/mdt205. View

Bergman A, Pinedo H, Talianidis I, Veerman G, Loves W, van der Wilt C . Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003; 88(12):1963-70. PMC: 2741118. DOI: 10.1038/sj.bjc.6601011. View

Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F . Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol. 2014; 140(10):1783-93. DOI: 10.1007/s00432-014-1715-2. View

Sjostrom J, Blomqvist C, Von Boguslawski K, Bengtsson N, Mjaaland I, Malmstrom P . The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res. 2002; 8(3):811-6. View

Kolb H, Finn M, Sharpless K . Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40(11):2004-2021. DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5. View

Nguyen C, Tran T, Amiji M, Lu X, Kasi R . Redox-sensitive nanoparticles from amphiphilic cholesterol-based block copolymers for enhanced tumor intracellular release of doxorubicin. Nanomedicine. 2015; 11(8):2071-82. PMC: 4628861. DOI: 10.1016/j.nano.2015.06.011. View

Xu P, Yu H, Zhang Z, Meng Q, Sun H, Chen X . Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis. Biomaterials. 2014; 35(26):7574-87. DOI: 10.1016/j.biomaterials.2014.05.030. View

Morton S, Lee M, Deng Z, Dreaden E, Siouve E, Shopsowitz K . A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal. 2014; 7(325):ra44. PMC: 4138219. DOI: 10.1126/scisignal.2005261. View

10.

Yuan X, Whang Y . PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene. 2002; 21(2):319-27. DOI: 10.1038/sj.onc.1205054. View

11.

Mangal S, Gao W, Li T, Zhou Q . Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017; 38(6):782-797. PMC: 5520191. DOI: 10.1038/aps.2017.34. View

12.

Palanikumar L, Al-Hosani S, Kalmouni M, Nguyen V, Ali L, Pasricha R . pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Commun Biol. 2020; 3(1):95. PMC: 7054360. DOI: 10.1038/s42003-020-0817-4. View

13.

Ma L, Xu Y, Su J, Yu H, Kang J, Li H . Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function. Int J Oncol. 2015; 47(5):1890-900. DOI: 10.3892/ijo.2015.3176. View

14.

Alexiou C, Schmid R, Jurgons R, Kremer M, Wanner G, Bergemann C . Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J. 2006; 35(5):446-50. DOI: 10.1007/s00249-006-0042-1. View

15.

Luo Z, Hu Y, Cai K, Ding X, Zhang Q, Li M . Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity. Biomaterials. 2014; 35(27):7951-62. DOI: 10.1016/j.biomaterials.2014.05.058. View

16.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

17.

Liu D, Hong Y, Li Y, Hu C, Yip T, Yu W . Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy. Theranostics. 2020; 10(3):1181-1196. PMC: 6956796. DOI: 10.7150/thno.38989. View

18.

Anselmo A, Mitragotri S . Nanoparticles in the clinic. Bioeng Transl Med. 2018; 1(1):10-29. PMC: 5689513. DOI: 10.1002/btm2.10003. View

19.

Shen J, Yin Q, Chen L, Zhang Z, Li Y . Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials. 2012; 33(33):8613-24. DOI: 10.1016/j.biomaterials.2012.08.007. View

20.

Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P . Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006; 17(8):1263-8. DOI: 10.1093/annonc/mdl104. View